Abstract: Objective To investigate the effectiveness of paclitaxel combined with carboplatin chemotherapy and radiotherapy in the treatment of advanced cervical cancer and its effect on squamous cell carcinoma antigen (SCCAg) and cytokeratin 19 fragmen 21-1(CYFRA21-1). Methods From February 2011 to February 2013, 62 patients with moderate and advanced cervical cancer treated in Qingdao Municipal Hospital were selected and divided into two groups according to different treatment methods, with 31 cases in each group. Patients in control group were treated with radiotherapy alone, while the observation group was treated with synchronous chemoradiotherapy. The clinical effectiveness, the changes of SCCAg and CYFRA21-1, the incidence of adverse reactions and the prognosis of the two groups were compared. Results There was no significant difference in age, pathological classification, FIGO stage, and menopausal status between the two groups. The total effective rate was 54.84% (17/31) in the control group and 83.87%(26/31) in the observation group, with statistically significant difference (P=0.013). After treatment, SCCAg and CYFRA21-1 in control group were significantly higher than observation group (SCCAg, 1.46±0.34 vs 0.99±0.24) μg/ml and (CYFRA21-1, 1.63±0.37 vs 1.02±0.31) μg/ml, and they decreased compared to those before treatment (all P< 0.05). The incidence rates of adverse reactions in the control group and the observation group were 32.26% (10/31) and 35.48% (11/31) (P=0.788). After 60-month follow-up, the survival rate was 3.23% (1/31) in the control group , significantly lower than 22.58% (7/31) in the observation group(P=0.014). The local recurrence rate and distant metastasis rate in the observation group were lower than those in the control group(all P< 0.05). Conclusion Paclitaxel combined with carboplatin chemotherapy and radiotherapy can down-regulate expression level of SCCAg and CYFRA21-1, which is an effective and safe way for moderate and advanced cervical cancer.